Patents Examined by M Franco G Salvoza
  • Patent number: 10172935
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: January 8, 2019
    Assignee: CureVac AG
    Inventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
  • Patent number: 10167333
    Abstract: The invention is in the field of medical treatment and prevention. The invention provides an antibody or a part thereof capable of specifically binding to the Hepatitis B surface antigen (HBsAg) and having Hepatitis B Virus (HBV) neutralizing activity, wherein said antibody or fragment thereof comprises a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 5, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 6, a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 7, a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 8, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 9 and a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 10.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: January 1, 2019
    Inventor: Mario Umberto Francesco Mondelli
  • Patent number: 10166188
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for vitrifying biological preparations, including peptides, antigens, antibodies, cells, and the like.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: January 1, 2019
    Assignee: MERIAL, INC.
    Inventor: Noel Yves Henri Jean Genin
  • Patent number: 10155023
    Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 18, 2018
    Assignee: CALDER BIOSCIENCES INC.
    Inventor: Christopher Patrick Marshall
  • Patent number: 10137186
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
  • Patent number: 10125187
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71).
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: November 13, 2018
    Assignee: MAB Explorations Sdn Bhd
    Inventor: Mary Jane Cardosa
  • Patent number: 10124060
    Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: November 13, 2018
    Assignee: University of Massachusetts
    Inventors: Shan Lu, Shixia Wang
  • Patent number: 10119125
    Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: November 6, 2018
    Assignees: Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute
    Inventors: Luk H. Vandenberghe, Eric Zinn
  • Patent number: 10119967
    Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: November 6, 2018
    Assignee: Institut Pasteur
    Inventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
  • Patent number: 10111947
    Abstract: The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: October 30, 2018
    Assignee: Transgene S.A.
    Inventors: Claude Sene, Mélina Chasle
  • Patent number: 10106781
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: October 23, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Patent number: 10100101
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: October 16, 2018
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood
  • Patent number: 10092638
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: October 9, 2018
    Assignees: DUKE UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • Patent number: 10087493
    Abstract: The present invention provides methods for detecting viral infectivity and content in an enzyme preparation. In certain embodiments, the invention relates to methods for producing a pharmaceutical pancreatic enzyme composition. In additional embodiments, the invention relates to detecting infectious porcine parvovirus (PPV) and determining PPV content in pancreatic enzyme preparations (PEPs), including pancrelipase preparations.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: October 2, 2018
    Assignee: APTALIS PHARMA CANADA ULC
    Inventors: Peter Tijssen, Jozsef Szelei, Zoltan Zadori
  • Patent number: 10086062
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 2, 2018
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood
  • Patent number: 10058603
    Abstract: The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Guy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
  • Patent number: 10047347
    Abstract: The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells while sparing normal cells.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: August 14, 2018
    Assignee: Ixogen Ltd.
    Inventor: Hans Daniel Öberg
  • Patent number: 10041090
    Abstract: Adeno-associated virus rh.8 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 7, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10035825
    Abstract: The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: July 31, 2018
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Terence Flotte, Jun Xie
  • Patent number: 10006841
    Abstract: Trapping devices and methods are provided for capturing a medical analyte, in blood or another biological fluid. The device may include a structural substrate and a binding agent, such as an antibody, affixed to the structural substrate, wherein the binding agent is capable of binding or attaching with a medical analyte, such as a viral particle, and the device is configured for placement in a biological cavity or vessel (containing a biological fluid) in a patient. The trapping device, which may be in a twisted coil shape, is configured to trap at least some of the medical analyte, such a viral particle, present in the biological fluid. The method may include deploying a trapping device into the patient's blood vessel; after a period following the deployment, removing the trapping device from the biological cavity or blood vessel; and then analyzing the trapping device for the presence of the medical analyte.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 26, 2018
    Assignees: Massachusetts Institute of Technology, Lahey Clinic Foundation, Inc.
    Inventors: Michael J. Cima, Gregory J. Ekchian, Christophoros C. Vassiliou, Vincent H. Liu, Christoph Wald, Sebastian Flacke, Fredric D. Gordon